Literature DB >> 23418241

Zoster vaccine.

Michael R Kolber1, Christina Korownyk, Tony Nickonchuk.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23418241      PMCID： PMC3576943     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  13 in total

1.  Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population.

Authors:  Hung Fu Tseng; Margaret Chi; Ning Smith; Stephen M Marcy; Lina S Sy; Steven J Jacobsen
Journal:  J Infect Dis       Date:  2012-06-04       Impact factor: 5.226

2.  The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study.

Authors:  Mélanie Drolet; Marc Brisson; Kenneth E Schmader; Myron J Levin; Robert Johnson; Michael N Oxman; David Patrick; Caty Blanchette; James A Mansi
Journal:  CMAJ       Date:  2010-10-04       Impact factor: 8.262

3.  Improving rates of herpes zoster vaccination with a clinical decision support system in a primary care practice.

Authors:  Rajeev Chaudhry; Sidna M Schietel; Fred North; Ramona Dejesus; Rebecca L Kesman; Robert J Stroebel
Journal:  J Eval Clin Pract       Date:  2012-02-05       Impact factor: 2.431

4.  Herpes zoster recurrences more frequent than previously reported.

Authors:  Barbara P Yawn; Peter C Wollan; Marge J Kurland; Jennifer L St Sauver; Patricia Saddier
Journal:  Mayo Clin Proc       Date:  2011-01-10       Impact factor: 7.616

5.  Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.

Authors:  K E Schmader; M N Oxman; M J Levin; G Johnson; J H Zhang; R Betts; V A Morrison; L Gelb; J C Guatelli; R Harbecke; C Pachucki; S Keay; B Menzies; M R Griffin; C Kauffman; A Marques; J Toney; P M Keller; X Li; I S F Chan; P Annunziato
Journal:  Clin Infect Dis       Date:  2012-07-24       Impact factor: 9.079

6.  Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial.

Authors:  Michael S Simberkoff; Robert D Arbeit; Gary R Johnson; Michael N Oxman; Kathy D Boardman; Heather M Williams; Myron J Levin; Kenneth E Schmader; Lawrence D Gelb; Susan Keay; Kathleen Neuzil; Richard N Greenberg; Marie R Griffin; Larry E Davis; Vicki A Morrison; Paula W Annunziato
Journal:  Ann Intern Med       Date:  2010-05-04       Impact factor: 25.391

7.  Management and prevention of herpes zoster: A Canadian perspective.

Authors:  Guy Boivin; Roman Jovey; Catherine T Elliott; David M Patrick
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

8.  Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.

Authors:  Kenneth E Schmader; Myron J Levin; John W Gnann; Shelly A McNeil; Timo Vesikari; Robert F Betts; Susan Keay; Jon E Stek; Nickoya D Bundick; Shu-Chih Su; Yanli Zhao; Xiaoming Li; Ivan S F Chan; Paula W Annunziato; Janie Parrino
Journal:  Clin Infect Dis       Date:  2012-01-30       Impact factor: 9.079

Review 9.  Decision aids for people facing health treatment or screening decisions.

Authors:  Dawn Stacey; Carol L Bennett; Michael J Barry; Nananda F Col; Karen B Eden; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Anne Lyddiatt; France Légaré; Richard Thomson
Journal:  Cochrane Database Syst Rev       Date:  2011-10-05

10.  Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases.

Authors:  Jie Zhang; Fenglong Xie; Elizabeth Delzell; Lang Chen; Kevin L Winthrop; James D Lewis; Kenneth G Saag; John W Baddley; Jeffrey R Curtis
Journal:  JAMA       Date:  2012-07-04       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.